Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia
The University of Sydney · Northern Sydney Local Health District · +1 more institution
Abstract
Lung cancer remains the leading cause of cancer-related mortality globally. While immune checkpoint inhibitors (ICIs) are the standard of care for metastatic non-small cell lung cancer (NSCLC), real-world data from Australia are limited. We conducted a population-based cohort study using national Pharmaceutical Benefits Scheme and National Death Index data, accessed via the Australian Bureau of Statistics DataLab. Adults initiating pembrolizumab monotherapy for metastatic NSCLC (2017-2022) were included. Overall survival (OS) and time to treatment discontinuation (TTD) were assessed using Kaplan-Meier analyses and multivariate Cox regressions. Immune-related adverse events (irAEs) were inferred from incident…
Citation impact
- FWCI
- 48.51
- Percentile
- 99%
- References
- 44
Authors
3- CHChin Hang Yiu
The University of Sydney, Northern Sydney Local Health District
- SJStephen J. Clarke
The University of Sydney, Royal North Shore Hospital, Northern Sydney Local Health District
- CYChristine Y. LuCorresponding
The University of Sydney, Royal North Shore Hospital, Northern Sydney Local Health District
Topics & keywords
- Pembrolizumab
- Levothyroxine
- Lung cancer
- Proportional hazards model
- Discontinuation
- Cohort
- Adverse effect
- Hazard ratio
- Good health and well-being